Patents by Inventor Dennis VERZIJL

Dennis VERZIJL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies
    Patent number: 11970544
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 30, 2024
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES BINDING AXL
    Publication number: 20240091352
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 28, 2023
    Publication date: March 21, 2024
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20230321261
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: September 30, 2022
    Publication date: October 12, 2023
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER
    Publication number: 20230257479
    Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Type: Application
    Filed: September 11, 2020
    Publication date: August 17, 2023
    Inventors: David SATIJN, Esther C.W. BREIJ, Bart E.C.G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN, Reshma Abdulla RANGWALA, Sri GHATTA, Ruud BRAKENHOFF, Rieneke VAN DE VEN
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20230087745
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ, Edward VAN DEN BRINK, Dennis VERZIJL
  • ANTIBODIES
    Publication number: 20220324980
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 15, 2022
    Publication date: October 13, 2022
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W BREIJ
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 11459395
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 4, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van den Brink, Dennis Verzijl
  • Antibodies
    Patent number: 11261254
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: March 1, 2022
    Assignee: GENMAB A/S
    Inventors: Louise Koopman, Patrick Engelberts, Dennis Verzijl, Edward N. Van Den Brink, Rik Rademaker, Sieto Bosgra, Frederikke L. Egerod, David Satijn, Esther C. W. Breij
  • ANTIBODIES
    Publication number: 20220049013
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 17, 2022
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • ANTIBODIES
    Publication number: 20220048999
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 17, 2022
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • Antibodies
    Patent number: 11130819
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: September 28, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES
    Publication number: 20210292418
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 17, 2021
    Publication date: September 23, 2021
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • ANTIBODIES
    Publication number: 20210230296
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • Antibodies
    Patent number: 11008399
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES
    Publication number: 20210070877
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: October 22, 2020
    Publication date: March 11, 2021
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20200397913
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 24, 2020
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel Simon PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • Antibodies binding AXL
    Patent number: 10765743
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 8, 2020
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • ANTIBODIES
    Publication number: 20200277397
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 9, 2020
    Publication date: September 3, 2020
    Inventors: David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
  • ANTIBODIES AGAINST PD-L1
    Publication number: 20200239579
    Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: March 9, 2018
    Publication date: July 30, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rik RADEMAKER, Paul PARREN, Bart DE GOEIJ
  • ANTIBODIES BINDING AXL
    Publication number: 20200171152
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: November 4, 2019
    Publication date: June 4, 2020
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA